Over the last 7 days, the United States market has remained flat, yet it is up 5.7% over the past year with earnings forecasted to grow by 13% annually. In this context of steady growth, identifying ...

Charlottesville's Burnley-Moran Elementary School won't just have a new name next school year, but a new principal too.

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers through a biotech industry ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...